Leopold Öhler

1.4k total citations
49 papers, 478 citations indexed

About

Leopold Öhler is a scholar working on Oncology, Hematology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Leopold Öhler has authored 49 papers receiving a total of 478 indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Oncology, 23 papers in Hematology and 15 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Leopold Öhler's work include Acute Myeloid Leukemia Research (13 papers), Colorectal Cancer Treatments and Studies (13 papers) and Cancer Treatment and Pharmacology (11 papers). Leopold Öhler is often cited by papers focused on Acute Myeloid Leukemia Research (13 papers), Colorectal Cancer Treatments and Studies (13 papers) and Cancer Treatment and Pharmacology (11 papers). Leopold Öhler collaborates with scholars based in Austria, Germany and United States. Leopold Öhler's co-authors include Klaus Geißler, Klaus Lechner, Eva Kabrna, Marietta Kollars, Manuela Födinger, Sonja Skoupy, Laurenz Vormittag, W Hinterberger, Peter Valent and Wolfgang Schima and has published in prestigious journals such as The Journal of Experimental Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Leopold Öhler

47 papers receiving 466 citations

Peers

Countries citing papers authored by Leopold Öhler

Since Specialization

Citations

This map shows the geographic impact of Leopold Öhler's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Leopold Öhler with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Leopold Öhler more than expected).

Fields of papers citing papers by Leopold Öhler

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Leopold Öhler. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Leopold Öhler. The network helps show where Leopold Öhler may publish in the future.

Co-authorship network of co-authors of Leopold Öhler

This figure shows the co-authorship network connecting the top 25 collaborators of Leopold Öhler. A scholar is included among the top collaborators of Leopold Öhler based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Leopold Öhler. Leopold Öhler is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Fifth-line HER2-directed therapy for metastatic adenocarcinoma of the gastroesophageal junction 2023 ·memo - Magazine of European Medical Oncology ·Sophie Roider‐Schur, (unknown), Leopold Öhler	0
2	SARS-CoV-2-related mortality and treatment delays for cancer patients in Austria 2022 ·Wiener klinische Wochenschrift ·J.M. Berger, (unknown), Oliver Königsbrügge, Hanna A. Knaus, Edit Porpaczy, H. Kaufmann, (unknown), (unknown), Thomas Winder, (unknown), Dominik Wolf‎, Verena Petzer, Van Anh Nguyen, Georg Weinlich, Leopold Öhler, Anna Wonnerth, (unknown), (unknown), Matthias Preusser, Anna S. Berghoff	1
3	Efficacy and safety of everolimus plus exemestane in patients with HR+, HER2− advanced breast cancer progressing on/after prior endocrine therapy in routine clinical practice: Primary results from the non-interventional study, STEPAUT 2020 ·The Breast ·Guenther G. Steger, Daniel Egle, Rupert Bartsch, Georg Pfeiler, Edgar Petru, Richard Greil, Ruth Helfgott, Christian Marth, Leopold Öhler, Michael Hubalek, Alois Lang, Christoph Tinchon, Ferdinand Haslbauer, (unknown), Karin Hock, (unknown), (unknown), Michael Gnant	13
4	172P REACHAUT: Real-world study of first-line (1L) ribociclib (RIB) + endocrine therapy (ET) in HR+, HER2- metastatic breast cancer (MBC) 2020 ·Annals of Oncology ·CF Singer, Daniel Egle, Richard Greil, Leopold Öhler, Edgar Petru, (unknown), Maximilian Marhold, Georg Pfeiler, Christine Brunner, Christoph Tinchon, (unknown), A. Galid, Ursula Pluschnig, Ferdinand Haslbauer, Michael Hubalek, (unknown), (unknown), (unknown), (unknown), Rupert Bartsch	1
5	Transferrin receptor 1 is a cellular receptor for human heme-albumin 2020 ·Communications Biology ·(unknown), (unknown), Madhura Modak, (unknown), (unknown), (unknown), Gerhard J. Zlabinger, Peter Steinberger, Janet Chou, Raif S. Geha, Leopold Öhler, Akihiro Yachie, Hyeryun Choe, (unknown), Hannes Stockinger, Johannes Stöckl	30
6	REGO-ACT: assessment of physical activity during treatment with regorafenib for metastatic colorectal cancer 2020 ·Wiener klinische Wochenschrift ·(unknown), Laurenz Vormittag, Leopold Öhler, Birgit Grünberger, Johannes Meran, (unknown), Johannes Andel, Wolfgang Eisterer, (unknown), Josef Thaler	3
7	Ramucirumab plus paclitaxel or FOLFIRI in platinum-refractory advanced or metastatic gastric or gastroesophageal junction adenocarcinoma—experience at two centres 2020 ·Journal of Gastrointestinal Oncology ·Ursula Vogl, Laurenz Vormittag, Thomas Winkler, (unknown), (unknown), (unknown), Sophie Roider‐Schur, (unknown), (unknown), Wolfgang Schima, Alexander Klaus, Johannes Zacherl, (unknown), Leopold Öhler	7
8	Safety and effectiveness of regorafenib in patients with metastatic colorectal cancer in routine clinical practice in the prospective, observational CORRELATE study 2019 ·European Journal of Cancer ·Michel Ducreux, Lone Nørgård Pétersen, Leopold Öhler, Francesca Bergamo, Jean‐Philippe Metges, Jan Willem de Groot, Jaw‐Yuan Wang, (unknown), (unknown), (unknown), Andrés Cervantes, Juan Manuel O’Connor, Alfredo Falcone	44
9	Nab-paclitaxel and gemcitabine or FOLFIRINOX as first-line treatment in patients with unresectable adenocarcinoma of the pancreas: does sequence matter? 2019 ·BMC Cancer ·Ursula Vogl, (unknown), Alexander Klaus, Laurenz Vormittag, Wolfgang Schima, (unknown), (unknown), Thomas Winkler, Leopold Öhler	42
10	Evaluation of Prognostic Immune Signatures in Patients with Breast, Colorectal and Pancreatic Cancer Receiving Chemotherapy 2017 ·Anticancer Research ·Ursula Vogl, Leopold Öhler, (unknown), Josa M. Frischer, Madhura Modak, Johannes Stöckl	8
11	P-179 Gemcitabine plus nab-Paclitaxel in metastatic or locally inoperable pancreatic cancer – a single center experience 2015 ·Annals of Oncology ·Ursula Vogl, Laurenz Vormittag, Thomas Winkler, (unknown), Michael D. Henry, Wolfgang Schima, Alexander Klaus, Johannes Zacherl, Leopold Öhler	2
12	Human leukaemic stem cells: a novel target of therapy 2004 ·European Journal of Clinical Investigation ·Wolfgang R. Sperr, Alexander W. Hauswirth, Stefan Florian, Leopold Öhler, Klaus Geißler, Peter Valent	22
13	Circulating myeloid colony-forming cells predict survival in myelodysplastic syndromes 2003 ·Annals of Hematology ·A. Berer, Eliézer Jäger, Verena Sagaster, Berthold Streubel, Friedrich Wimazal, Wolfgang R. Sperr, (unknown), Ilse Schwarzinger, Florian Frommlet, Oskar A. Haas, Peter Valent, Klaus Lechner, Klaus Geißler, Leopold Öhler	8
14	Numbers of colony‐forming progenitors in patients with systemic mastocytosis: potential diagnostic implications and comparison with myeloproliferative disorders 2003 ·European Journal of Clinical Investigation ·John-Hendrik Jordan, Eliézer Jäger, Wolfgang R. Sperr, Ilse Schwarzinger, Manuela Födinger, Robert Fritsche‐Polanz, Leopold Öhler, Klaus Geißler, Peter Valent	5
15	Relation of In Vitro Growth Characteristics to Cytogenetics and Treatment Outcome in Acute Myeloid Leukemia: Prognostic Significance in Patients with a Normal Karyotype 2003 ·International Journal of Hematology ·A. Berer, Birgit Kainz, Ulrich Jäger, (unknown), (unknown), Berthold Streubel, Christa Fonatsch, Gerlinde Mitterbauer, Klaus Lechner, Klaus Geißler, Leopold Öhler	1
16	Cytogenetic risk groups in acute myeloblastic leukaemia differ greatly in their semi‐solid colony growth 2001 ·British Journal of Haematology ·Leopold Öhler, A. Berer, Daniel Aletaha, Eva Kabrna, Georg Heinze, Berthold Streubel, Christa Fonatsch, Oskar A. Haas, Klaus Lechner, Klaus Geißler	10
17	Decrease of Circulating Hematopoietic Progenitor Cells During Interleukin-2 Treatment is Associated with an Increase of Vascular Cell Adhesion Molecule-1, a Critical Molecule for Progenitor Cell Adhesion 2000 ·Leukemia & lymphoma ·Gottfried J. Locker, Brigitte Stoiser, Heidrun Losert, Catharina Wenzel, Leopold Öhler, (unknown), Klaus Geißler	5
18	Interleukin 10 inhibits growth and granulocyte/macrophage colony-stimulating factor production in chronic myelomonocytic leukemia cells. 1996 ·The Journal of Experimental Medicine ·Klaus Geißler, Leopold Öhler, Manuela Födinger, Irene Virgolini, M. Leimer, Eva Kabrna, Marietta Kollars, Sonja Skoupy, Barbara Bohle, Michael A. Rogy, Klaus Lechner	49
19	Effect of interleukin‐3 pretreatment on granulocyte/macrophage colony‐stimulating factor induced mobilization of circulating haemopoietic progenitor cells 1995 ·British Journal of Haematology ·Klaus Geißler, Christian Peschel, Dietger Niederwieser, Jutta Goldschmitt, Florian Hladik, (unknown), Leopold Öhler, Peter Bettelheim, (unknown), Klaus Lechner, P Höcker, Karin Kolbe	15
20	Granulocyte colony-stimulating factor (rh G-CSF) as an adjunct to interferon alpha therapy of neutropenic patients with hairy cell leukemia 1993 ·Annals of Hematology ·C. Lorber, Andrea Willfort, Leopold Öhler, Ulrich Jäger, Ilse Schwarzinger, Klaus Lechner, Klaus Geißler	10

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact